These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 26417275)

  • 21. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
    Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.
    Castillo V; Figueroa F; González-Pizarro K; Jopia P; Ibacache-Quiroga C
    Foods; 2021 Jul; 10(8):. PubMed ID: 34441497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut Microbiota: Association with NAFLD and Metabolic Disturbances.
    Lau E; Carvalho D; Freitas P
    Biomed Res Int; 2015; 2015():979515. PubMed ID: 26090468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
    Tokuhara D
    Front Nutr; 2021; 8():700058. PubMed ID: 34250000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiological role of host microbiota in the development of obesity.
    Kobyliak N; Virchenko O; Falalyeyeva T
    Nutr J; 2016 Apr; 15():43. PubMed ID: 27105827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach.
    Sangouni AA; Ghavamzadeh S
    Diabetes Metab Syndr; 2019; 13(5):2917-2922. PubMed ID: 31425956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Microbiota and Lifestyle Interventions in NAFLD.
    Houghton D; Stewart CJ; Day CP; Trenell M
    Int J Mol Sci; 2016 Mar; 17(4):447. PubMed ID: 27023533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease.
    Lambertz J; Weiskirchen S; Landert S; Weiskirchen R
    Front Immunol; 2017; 8():1159. PubMed ID: 28970836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
    Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
    Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease.
    Zhang Q; Xing W; Wang Q; Tang Z; Wang Y; Gao W
    Front Nutr; 2022; 9():934113. PubMed ID: 36204383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiome and metabolic diseases.
    Fukuda S; Ohno H
    Semin Immunopathol; 2014 Jan; 36(1):103-14. PubMed ID: 24196453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the microbiome in NAFLD and NASH.
    Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.